Impact of the presence of extra-core monosaccharides on IgG ADCC and CDC effector functions.
The first monoclonal antibody (Mab), developed against kidney transplant rejection, was accepted by the FDA in 1986 . Today, Mabs are leading the biotherapeutics market as 28 have been approved in Europe and the USA, and hundreds are in clinical trials [2-4]. Most of them are of IgG1 subtype, developed for cancer and immune disease treatments. Mabs clinical efficacy not only relies on specific target binding provided by their variable region, but also on their ability to trigger defense mechanisms such as antibody-dependent cellular cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC). These effector functions are mediated by the interaction between the antibody Fc fragment and the Fcγ-receptors expressed on immune cell surfaces or the molecules of the complement involved in ADCC and CDC respectively. In the last decade, these interactions were found to be highly dependent on on the presence and structure of the N-glycan linked to the Fc fragment [5, 6].
Fc fragments possess two conserved N-glycosylation sites on asparagine 297 in the CH2 domain of each heavy chain. Mabs produced in mammalian cells possess a wide variety of glycoforms, as the attached glycans are modified to different extents with core-fucosylation, bisecting N-acetylglucosamine addition, galactosylation and sialylation. The glycan composition is crucial, as the presence or absence of a single monosaccharide residue can remarkably affect the affinity of the Mab for the different Fcγ-receptors. Among the variety of monosaccharides present on Fc glycans, terminal sialic acids are particularly interesting, as their role in Mab functions is both positive and negative. Sialylation of the Fc glycan dramatically decreases Mab affinity for the canonical Fc receptors, thereby inhibiting ADCC. However, recent studies on the anti-inflammatory properties of intravenous immunoglobulins (IVIg) suggest that this biological activity could be conferred by the presence of α2,6-sialic acid residues on the Fc glycans. Although this hypothesis is still controversial, the study has raised a new interest in α2,6-sialylated IgGs. While glycosylation of therapeutic Mabs significantly impact their biological activity, the production of Mabs with a specific homogenous glycoform profile is in general beyond the reach of manufacturing bioprocesses. In this chapter, we describe and compare two large-scale transient expression platforms using chinese hamster ovary (CHO) and human embryonic kidney 293 (HEK293) cells for the production of highly sialylated monoclonal antibodies.
2. IgG N-glycans and their interactions with the Fc
Glycosylation is a complex process that involves several glycosyltransferases and glycosidases. Most glycosylation sites are located on the glycoprotein surface, whereas IgGs’ N-glycans are embedded within the Fc fragment. This particular location restricts the access of glycosyltransferases to their substrates, thereby reducing glycan complexity. Subsequently, while tri- and tetra-antennary glycans can be found on many glycoproteins such as EPO or IgG Fab fragments, Fc N-glycans are of the complex biantennary type  that consists of a heptasaccharide core structure comprising four N-acetylgalactosamines (GlcNAc) and three mannoses (Figure 1). The α1,3 and α1,6 arms can be further elongated with galactose and sialic acid. Fucose and bisecting-GlcNAc can be found on the core GlcNAc and on the central mannose respectively. This glycan is rarely fully processed; the predominant glycoform found on antibodies produced in CHO and 293 cell cultures is the fucosylated core-structure.
The CH2 amino acid sequence around Asn297 is very well conserved amongst IgG subtypes. Several amino acids have been shown to interact with the glycan located on the same heavy chain (HC), whereas no interaction is likely to happen with the other heavy chain. Amino acid-glycan interactions determine the glycan position within the Fc pocket and its availability for glycosyltransferases. The galactose (Gal) on the α1,6 arm is the main residue retaining the glycan on the protein surface [6, 8, 9] by generating H-bonds with Lys246 and Thr260 . In IgG1 and IgG4 subtypes, galactosylation occurs preferentially on α1,6 branch [8, 10]. The inner saccharides have less interaction with the protein. The first and second GlcNAc residues generate H-bonds with Asp265 and Arg301 respectively . They also form a CH/π interaction with the non-polar moieties of Val264 and Phe241 . Similarly, the GlcNAc residue on the α1,6 branch also forms a CH/π interaction with Phe243 . In contrast to galactosylation, sialylation preferentially occurs on the α1,3 arm. It has been suggested that the galactose on the α1,6 arm may limit further elongation by maintaining the branch close to the CH2 protein surface . However, even if steric hindrance may play a role, branch α2,6-sialylation specificity was shown to be a consequence of ST6Gal-I α1,3 arm preference , a phenomenon that is protein independent. The presence or absence of a sugar residue on the Fc glycan thus affects the conformation of the Fc, thereby affecting the Fc-mediated effector functions. These effects are summarized in Table 1.
|Impacted effector function||Reference|
|Fucose||-||ADCC||Shields 2002, Shinkawa 2003|
|Sialic acid||-||ADCC||Scallon 2007|
3. Sialic acids in Fc N-glycans
The half-life of a number of glycoproteins can be enhanced by sialylation, as sialic acid acts as a cap that hides the penultimate galactose residue recognized by the hepatic asialoglycoprotein receptor (ASGPR, or Ashwell-Morell receptor) . Sialic acid can be linked to the galactose either with α2,3 or α2,6 linkage. Recent studies showed that α2,3 sialylation provides a better protection to the protein than α2,6 sialylation, as ASGPR recognizes Siaα2,6Gal and Siaα2,6GalNAc moieties in addition to the well-known Gal and GalNAc residues [14, 15]. However, Fc-glycans have no apparent impact on IgG half-life . The benefits of IgG sialylation on
IVIg are IgGs pooled and purified from sera of 3000 to 10000 donors. The sialylated fraction represents around 10% of the total IgGs present in the pool. To be therapeutically effective, IVIg used as an anti-inflammatory drug require repeated injections of very high doses (1-3g/kg). As IVIg are successfully used in an increasing number of applications, a lack of donors is expected in the near future [23, 24]. To increase the therapeutic efficacy of anti-inflammatory IgGs and avoid IVIg shortage, one strategy may reside in the production of recombinant sialylated IgGs .
4. Production of sialylated recombinant antibody
The CHO cell line is the most widely accepted production cell line in the industry for therapeutic manufacturing, including monoclonal antibodies. CHO cells have proven to be a safe expression system and provide high production yields. IgG and Fc fragment produced in CHO cells exhibit a very low level of sialylation (<2%). However, it was shown that a single mutation in the CH2 domain, the replacement of Phe243 by an alanine, enhances the sialylation level of an IgG3 . CHO glycosylation machinery is very similar to that found in human cells but with two major differences: they lack a functional N-acetylglucosaminyltransferase-III (GnTIII) for the addition of bisecting-GlcNAc and, more importantly, they lack the alpha-2,6-sialyltransferase-I activity (ST6Gal-I or SIAT1) responsible for the addition of sialic acids on galactose residues with α2,6 an linkage . The expression of a recombinant ST6Gal-I is therefore necessary to achieve the production of α2,6 sialylated IgGs in CHO cells.
Large-scale transfection strategies allow for the rapid expression of recombinant glycoproteins. The HEK293 cell line is easily transfectable with a variety of gene transfer reagents, and is probably the most utilized cell line for large-scale transient gene expression [28, 29]. More recently, approaches using CHO cells have also been developed that provide tens to hundreds of milligrams of protein per litre . In order to generate high titres of antibodies with enhanced α2,6-sialylation, we optimized the conditions for the transient co-expression of human ST6Gal-I together with IgG light and heavy chains in CHO and HEK293 cells. Our model antibody, Herceptin (or trastuzumab, herein abbreviated TZM), is a humanized mouse IgG1 used in the treatment of HER2-positive breast cancer. TZM has no glycosylation site on the Fab fragment but only the N297 sites on each CH2 domains of the Fc. We compared sialylation of the wild-type antibody to the F246A mutant (TZMm), which is equivalent to the IgG3 F243A mutant described previously .
5. Materials and methods
Mammalian. cell culture
The human embryonic kidney 293-6E cell line stably expressing truncated Epstein-Barr virus Nuclear Antigen-1 (EBNA1) and the Chinese hamster ovary cell line also expressing a truncated EBNA1 protein (clone 3E7, or CHO-3E7) were grown in suspension culture in serum-free F17 medium (Invitrogen, Carlsbad, CA) supplemented with 0.1% Pluronic-F68, 25 µg/mL geneticin G418 (for 293-6E cells only) and 4 mM glutamine . Cultures were maintained between 0.1 and 2.0 x 106 cells/mL in 125 mL ventilated Erlenmeyer flasks shaken at 120 rpm in a humidified incubator at 37°C with 5% CO2.
The light (LC), heavy (HC), and F246A mutated heavy (HCF246A) chains were cloned between the EcoRI and BamHI sites of the pTT5 vector [32, 33]. The human ST6Gal1 gene was cloned between the HindIII and BamHI sites of the pYD7 vector . Green fluorescent protein (GFP) cloned into the pTT vector was used as a reporter gene to evaluate transfection efficiency . Plasmids were amplified in Escherichia coli (DH5α) grown overnight in CircleGrow medium (MP Biomedical, Solon, OH) supplemented with 100ug/mL ampicillin and purified using MAXIprep or QIAprep spin Miniprep columns (Qiagen, Mississauga, ON).
Linear 25 kDa polyethylenimine "Use of PEI for transfection may be covered by existing intellectual property rights, including US Patent 6,013,240, European Patent 0,770,140, and foreign equivalents for which further information may be obtained by contacting firstname.lastname@example.org”
"Use of PEI for transfection may be covered by existing intellectual property rights, including US Patent 6,013,240, European Patent 0,770,140, and foreign equivalents for which further information may be obtained by contacting email@example.com”
Purification. of Mabs from cell culture supernatants
Cell cultures were centrifuged 20 min at 3000g. The supernatant was collected and loaded on a 4mL MabSelect SuRe column (GE Healthcare, Mississauga, ON) equilibrated in PBS. The column was washed with PBS and Mabs were eluted with 100mM citrate buffer pH 3.0. The fractions containing Mabs were pooled and the citrate buffer was exchanged against water on Econo-Pac® 10DG columns (Bio-Rad, Mississauga, ON). Purified Mabs were sterilized by passing through 0.2 μm filters, aliquoted, and stored at -80°C.
Quantification. of Mabs
Concentration of TZM and TZMm in culture supernatants were determined by protein-A HPLC using a 800 μL POROS® 20 micron Protein A ID Cartridge (Applied BioSystems, Foster City, CA) according to the manufacturer’s recommendations. The antibody present in the culture medium was also visualized following reducing and non-reducing SDS-PAGE stained by Bio-Safe Coomassie Stain (Bio-Rad, Mississauga, ON). Purified Mab were quantified by absorbance at 280 nm using a Nanodrop™ spectrophotometer (ThermoScientific).
Lectin-Blot. for α2,6-sialylation evaluation
α2,6 sialylation was assessed by lectin-blotting on denatured and reduced antibody to separate HC from LC. After protein transfer, nitrocellulose membrane was incubated 3 hours with biotinylated Sambucus Nigra (SNA) lectin (Vector Laboratories, Burlingame, CA), then incubated with Streptavidin-Peroxidase Polymer (Sigma, Saint Louis, MO) for one hour. Signal was revealed with BM Chemiluminescence Blotting Substrate (POD) (Roche Applied Science, Indianapolis, IN).
Isoelectric. focusing (IEF)
Purified Mabs were analysed on PhastGel™ 3-10, run on the PhastSystem™ (Amersham Biosciences, Baie d’Urfe, QC) according to the manufacturer’s recommendations. Gels were fixed in trichloroacetic acid (TCA) 5% in water (w/w) and stained with Coomassie blue 0.02%.
Enzymatic. removal of sialic acids
α2,3 linked sialic acids were enzymatically removed from the purified antibody by
Peptide-N-glycosidase F (PNGaseF) was purchased from Roche (Mannheim, Germany). Phenylhydrazine (PHN), phenylhydrazine hydrochloride (PHN.HCl), iodomethane (MeI), dimethylsulfoxide (DMSO), 2,5-dihydroxybenzoic acid (DHB) and 2-aza-2-thiothymine (ATT) were obtained from Sigma (St. Louis, MO, USA). Carbon and STRATA-X-C cartridges were purchased from Phenomenex (Torrance, CA). Solid sodium hydroxide (NaOH) and HPLC-grade solvents (acetonitrile (ACN), chloroform, methanol) were obtained from Fisher Scientific (Fair Lawn, NJ). HPLC-grade water was obtained with a Milli-Q® plus TOC water purification system (Millipore, Bedford, MA).
Release. of N-linked oligosaccharides from samples and MALDI-MS analysis
To the sample solution (100 µL; 50µg glycoprotein) 2 µL of PNGaseF were added and incubated at 37°C for 5-18 h. One µL of digested mixture was loaded onto a spot with freshly prepared matrix solution (0.8 µL; 5 mg of ATT and 2.5 mg of PHN.HCl dissolved in 350 µL 50% ACN in water) predeposited on the surface of a MALDI target. When the mixture was partially dried, 0.4 µL of PHN-labelling solution (phenylhydrazine:deionized water:ACN/1:4:1) was added to the spot with sample-matrix and left to air air-dry. The samples were analysed by MALDI-TOF/TOF-MS (UltrafleXtremeTM, Bruker) in both positive and negative ion modes. For the structural analysis individual parent ions were manually selected. MS/MS spectra of oligosaccharides were interpreted manually. The structures of N-glycans were derived on the basis of fragmentation patterns which were produced under MS/MS conditions for single precursor ions. For a discrimination of isomeric structures, general rules described in previous study have been applied .
To verify glycan profiles obtained by PHN-target derivatization immediately after PNGaseF treatment, all digested samples were also purified on STRATA-XC cartridges combined with carbon cartridges. After washing carbon cartridge with 4x1000µL of deionized water, glycans were eluted with 40% ACN (1000µL). After total evaporation the glycans were labelled with PHN as described above or permethylated according to the procedure described by Ciucanu and Kerek . Briefly, dried fractions containing oligosaccharides were dissolved in DMSO (40 µL), to which NaOH (2 mg) and methyl iodide (8 µL) were added. The mixture was vortexed vigorously (30 min) at room temperature. Then, the reaction was stopped by adding ice-cold water (500 µL) followed by chloroform (200 µL). After mixing and centrifugation, the upper aqueous layer was discarded and the chloroform portion was again washed with distilled water (4 X 500 µL each). Chloroform was evaporated and the sample was reconstituted in 70% aqueous methanol (5 µL).One µL of permethylated sample solution was spotted into DHB matrix and analysed by MS.
Intact. mass analysis of Mabs
The antibody isolates were analysed by Trap-LC-MS using an Agilent 1100 series HPLC system coupled to a Q-TOF2 hybrid quadrupole time-of-flight mass spectrometer (Waters) equipped with an electrospray interface. Approximately 3 µg of antibody was injected onto a Protein MicroTrap (Michrom BioResources/Dionex). The trap was washed with deionized water (~500 µL) to remove buffers prior to being switched on-line with the LC-MS system. The antibody was eluted using a linear gradient from 1% to 85% solvent B in 27min (solvent A: 0.1% formic acid, solvent B: 0.1% formic acid in acetonitrile, flow rate: 0.45mL/min). The mobile phase was split before the trap to 50µL/min. The electrospray voltage was 4200V and cone voltage was 80V. The Q-TOF2 mass spectrometer was calibrated for high mass range using cesium iodide. Mass spectra were acquired every 2 seconds during the analyses over the full mass range (m/z 50-4000). The mass spectra acquired across the protein peak were combined and smoothed (smooth window: ± 3, number of smooths: 8, smoothing method: Savitsky-Golay) and deconvoluted using the MassLynx MaxEnt 1 software from Waters: spectral window: m/z 2500-3200, molecular weight range: 140,000-160,000 Da, resolution: 1.00Da/channel, damage model: simulated isotope pattern spectrometer blur width of 0.500Da, minimum intensity ratios: 60% left, 60% right, number of iterations: 15). Peaks in the molecular weight profile were integrated using the MassLynx software.
6.1. Transfection conditions optimization
DNA. ratio parameters
Transfection efficacy relies on a variety of parameters that are, amongst others, cell line- protein- and plasmid-dependent. We expressed our model Mab together with the human α2,6 sialyltransferase (ST6Gal-I) by performing co-transfection of the Mab heavy chain (HC), light chain (LC) and ST6Gal-I expressing plasmids. The optimal proportions of each plasmid were determined to ensure 1) the proper assembly of the Mab, 2) high sialylation levels and 3) high Mab yields. The LC:HC and (LC:HC):ST6Gal-I ratios were then assessed in CHO and 293 cells in suspension in 6-well plates, after 5 days at 37°C. The supernatants were collected and analysed by protein-A HPLC (Fig. 2A) and by SDS-PAGE followed by Coomassie staining (Fig. 2B) to evaluate the expression yield and proper assembly of antibodies. Sialylation was assessed by SNA-blotting (Fig. 2C). For TZMm, a slight excess of LC plasmid (LC:HC of 6:4) provided a better expression yield in both cell lines. For wild-type TZM, this ratio was of 5:5 in 293 and 6:4 in CHO cells. A ratio 6:4 was chosen for the expression of TZM and TZMm in both cell lines. As for sialylation, 20% of ST6Gal-I plasmid was found to allow maximum signal in SNA blots without significantly affecting TZMm expression yields in both cell lines. It is worth noticing that the sialylation of the wild-type antibody remained very low for all ST6Gal-I plasmid ratios, suggesting the inability of the enzyme to sialylate TZM. Mab yields were increased in 293 cells with the incorporation of 30% of non-coding DNA (salmon sperm DNA) in the final DNA mix, while this was unnecessary in CHO cells (data not shown).
The usual polyethylenimine (PEI) mediated transfection protocol involves the formation of DNA-PEI complexes (polyplexes) prior to their addition to the cells. Another approach, the direct transfection, consists of the successive addition of DNA and PEI to the cell suspension, and was validated with 293 cells to facilitate large-scale transfection handling [46, 48]. This strategy was adapted here for CHO cells. 1.5 μg of DNA and 7 μg of PEI per mL of culture allowed the expression of amounts of IgGs equal to the classic indirect protocol (Fig. 3). Transfection parameters for CHO and 293 cells are summarized in Table 2.
|DNA:PEI for Direct protocol||1:3 (LPEI)||1.5:7 (PEI max)|
6.2. Mab expression and sialylation kinetics
Sialylation is likely to be limited after a certain time in batch culture due to a combination of adverse factors such as, but not limited to, ammonia accumulation [37, 38], ST6Gal-I plasmid loss upon successive cell division and sialidases release in medium . As Mab titre increases over time in the culture medium, the harvest time point selected must provide an acceptable compromise between high Mab yield and high sialylation. In this study, we gave priority to sialylation over Mab expression yield.
Sialylation kinetics was studied on the mutant antibody as sialylation of TZM was barely detectable. TZMm co-expression with ST6Gal-I was carried out for 7 days in 293 and CHO cells, until viability dropped to approximately 60% (Fig. 4A). A fraction of each culture was harvested daily from day 3 to day 7 and purified by protein-A affinity chromatography. Sialylation level of the purified TZMm fractions were assessed by SNA-blotting and IEF analyses.
In 293 cells, SNA-blot showed a maximum α2,6-sialylation on day 3, which then decreased over time (Fig. 5A). In CHO cells, no significant loss of intensity was observed, suggesting that α2,6-sialylation of the heavy chain was more stable over time. These patterns were supported by IEF analyses. Due to the negative charge of sialic acid, mono, di, tri and tetra-sialylated Mabs are expected to have lower pI than asialylated glycoforms. Even though these variations in pI are small, they could be easily distinguished on IEF gels. The upper band intensity showed a higher amount of asialylated glycoforms in 293 than in CHO as seen on the blot (Fig. 5B). The decline in the sialylation level was less obvious by IEF vs SNA-blot analysis for the 293 cells, which could be explained by a change in the α2,3 / α2,6 sialylation ratio over time. For CHO cells, the IEF profiles mirrored the SNA-blot results as there was no significant band intensity variation among the samples from day 3 to day 7. TZM and TZMm treated overnight with α2,3-6 neuraminidase (
6.3. Impact of ST6Gal-I expression and F246A mutation on sialylation patterns
Impact. of ST6Gal-I overexpression and F246A mutation on TZM sialylation
To evaluate the impact of ST6Gal-I expression on overall sialylation levels of TZM and TZMm, purified Mabs were submitted to SNA blotting and IEF analyses (Figure 6). While SNA blot (panel A) shows a significant increase in α2,6-sialylation levels of TZMm, no increase in sialylation of the wild-type antibody could be observed in 293 cells while only a faint band could be seen in CHO cells. In 293 cells, only a marginal signal with SNA lectin could be seen when TZMm was expressed alone, suggesting that endogenous levels of ST6Gal-I activity are low in this cell line. The main consequence of ST6Gal-I co-expression was the significant preference for α2,6-sialylation over α2,3-sialylation of TZMm in CHO cells. While all of the acidic TZMm species observed when the Mab was expressed alone disappeared after treatment with Sialidase S (an α2,3-specific neuraminidase), these acidic species became resistant to Sialidase S when ST6Gal-I was co-expressed. This suggests that sialylation of TZMm in the presence of ST6Gal-I was mostly due to the preferential addition of α2,6- over α2,3-sialic acid residues.
Glycan. analysis by MALDI-MS spectrometry
After PNGaseF digestion of the purified Mabs, oligosaccharide detection was firstly achieved by MALDI-MS directly after non-reductive on-target derivatization with phenylhydrazine (PHN) without using any purification procedure. Despite a presence of side products and salts coming from original buffer, which generally have a tendency to suppress signal peaks corresponding to glycans, all samples provided good evidence for the presence of N-glycans. These N-glycans were known to be located on the Fc fragment as Asparagine 297 is the only glycosylation site in our model antibody. The profile differences between the samples in CHO and 293 were consistent with what was observed by SNA-blot and IEF. The dominant oligosaccharides derived from all Mab samples were observed in positive mode in PHN-derivatized samples at
The spectra recorded in the negative mode from TZM samples co-expressed with ST6Gal-I and derivatized with PHN, provided evidence for the presence of small amount of monosialylated glycans structure - NeuAcGal1-2GlcNAc2Man3GlcNAc2Fuc (Figure 7A & 7E).
Sialylated glycans were clearly detected at higher levels in TZMm samples. TZMm samples co-expressed with ST6Gal-I in both cell lines (Fig. 7C & 7G) indicated higher sialylation degree than that obtained under control conditions (Fig. 7D & 7H).
The high level of sialylated glycans was even better observed in the fractions obtained after purification prior to derivatization, as shown in Figure 8 which represents MS spectra recorded from TZMm samples produced in 293 cells. Interestingly, this analysis revealed traces of triantennary glycans in TZMm that cannot naturally occur in wild-type IgG1, supporting the vision of an open Fc conformation presenting reduced space constraint to the glycosyltransferases.
Intact. mass analysis of antibodies by LC-ESI-MS using a Q-TOF2 spectrometer
The intact mass analysis approach allowed us to see the outcome of the pairing of the glycans on the overall glycosylation of the antibodies, and to distinguish with a high resolution between galactosylated and sialylated Mabs glycoforms. The prevalence of agalactosylated and monogalactosylated glycoforms in TZM+/-ST6 samples in both cell lines was consistent with the glycan analysis by MALDI-MS (Fig. 9A). No trace of sialylated
antibodies was detected. The close resemblance of the profiles of TZM produced in the presence or absence of ST6Gal-I confirmed the poor sialylation efficacy of the wild-type antibody. In contrast, the association of the Fc F246A mutation with the expression of ST6Gal-I in CHO cells resulted in a massive conversion of the neutral Mabs into a variety of mono-, di-, tri- and tetrasialylated antibodies, where the tetrasialylated version was predominant (Fig. 9B). The combination of the two approaches in 293 cells, as well as the Fc mutation alone in both cell lines provided intermediate results (not shown).
IVIg are successfully used for the treatment of an increasing number of autoimmune and inflammatory disorders. Their efficacy results from several distinct mechanisms working together in a complex fashion that is not yet understood. Anti-inflammatory mechanisms of IVIg may involve distinct pathways via FcRn or FcyRIIb receptors. Kaneko
Several approaches are used to enhance the sialylation level of recombinant proteins produced in mammalian cell cultures, such as cell line engineering, bioprocess control, post-production enrichment (such as lectin-affinity purification) and
The results obtained in this study were very similar to those of Jassal et al. on a monoclonal antibody of the IgG3 subtype . The replacement of phenylalanine 246, equivalent to F243 in IgG3, by an alanine residue was necessary to reach significant sialylation levels, and the impact of this mutation was much stronger than that of human ST6Gal-I over-expression in both 293 and CHO cell lines. This confirms that IgG1 Fc structure strongly limits glycan accessibility to the sialyltransferases. The intact mass analysis profile of the mutant co-expressed with ST6Gal-I in CHO was dominated by the fully sialylated Mab, followed by tri-, di- and monosialylated forms.
Replacing the phenylalanine with an alanine residue decreases the hydrophobic environment that maintains the glycan buried in the Fc. Multiple mutation strategies are a powerful mean to promote glycosylation enhancement and Fc affinity for FcγRs. Computational modeling allows the design of antibodies with amino acid mutations that are not even exposed on the surface of the glycan pocket. However, the accumulation of mutations in a therapeutic Mab can have unpredictable side effects . In the first place, mutation may compromise the affinity of the Mab for potential receptors involved in the anti-inflammatory mechanism. Also, non-natural Mab glycan structures (like sialylated tri-antennary glycans) may reduce their biological activity or even render them immunogenic. In a recent study, the CHO ST6Gal-I gene, present but not expressed, was cloned and stably expressed in these cells . As a result, 70% of the glycans of a stably expressed IgG1 and released by PNGaseF were sialylated. This striking result was thought to be conferred by a higher propensity of the CHO ST6Gal-I gene product for Fc glycan compared to its human or rat homologues, possibly due to some mutations in the substrate binding region. The use of this particular CHO ST6Gal-I gene may provide an interesting alternative strategy independent any IgG mutations to enhance sialylation of Mabs.
The production of highly sialylated IgGs in large quantities will probably be achieved by the simultaneous use of cell line engineering, Fc engineering, bioprocess control and downstream processing. Alternatively, optimizing
We thank Louis Bisson for protein-A HPLC quantifications.
- "Use of PEI for transfection may be covered by existing intellectual property rights, including US Patent 6,013,240, European Patent 0,770,140, and foreign equivalents for which further information may be obtained by contacting firstname.lastname@example.org”